Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shanghai Yongguan Adhesive Products Corp Ltd
SSE:603681
|
CN |
|
Rhoen Klinikum AG
XETRA:RHK
|
DE |
|
Baida Group Co Ltd
SSE:600865
|
CN |
|
Greenwave Technology Solutions Inc
NASDAQ:GWAV
|
US |
|
Orient Green Power Company Ltd
NSE:GREENPOWER
|
IN |
Clinuvel Pharmaceuticals Ltd
Total Current Assets
Clinuvel Pharmaceuticals Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Current Assets
AU$261.4m
|
CAGR 3-Years
19%
|
CAGR 5-Years
27%
|
CAGR 10-Years
37%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Assets
$202.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
17%
|
CAGR 10-Years
4%
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Assets
$11.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Current Assets
AU$21.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Assets
AU$330.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Assets
AU$153.7m
|
CAGR 3-Years
81%
|
CAGR 5-Years
22%
|
CAGR 10-Years
32%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Total Current Assets?
Total Current Assets
261.4m
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Total Current Assets amounts to 261.4m AUD.
What is Clinuvel Pharmaceuticals Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
37%
Over the last year, the Total Current Assets growth was 15%. The average annual Total Current Assets growth rates for Clinuvel Pharmaceuticals Ltd have been 19% over the past three years , 27% over the past five years , and 37% over the past ten years .
